Techniques for Detection of Minimal Residual Disease
- 1 January 1995
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 18 (sup1) , 75-80
- https://doi.org/10.3109/10428199509075308
Abstract
Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characterized by advantages and limitations, mainly related to its sensitivity and specificity. The general limitations of such tests originates from the size of the sample which can be analysed and the heterogeneous distribution of leukemia after treatment. Clinically useful methods for detecting residual leukemia require not only sensitivity but also speed and reproducibility. The rate of false negative tests is low with polymerase chain reaction as well as flow cytomeitric analysis. Usually, patients without persistent cells carrying leukemia-associated markers have a lower risk of relapse. However, the detection of a persistent marker at one time point in complete remission cannot be considered a reliable indicator of MRD, whereas increase of positive signals or reappearance of leukemic markers usually precedes relapse. It is likely that one single approach will not allow the monitoring of the majority of patients and that a combination of techniques will be needed. Definitive results will be obtained only through prospective studies in patients receiving standardised therapy. Studies in which therapeutic strategies are designed according to the results provided by techniques for detecting MRD will be necessary to assess the relevance of their contribution to the treatment of leukemia.Keywords
This publication has 15 references indexed in Scilit:
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual diseaseBlood, 1991
- Translocations, master genes, and differences between the origins of acute and chronic leukemiasCell, 1991
- The use of the polymerase chain reaction for the detection of minimal residual malignant disease [editorial]Blood, 1991
- Detection of T-cell receptor gamma chain V gene rearrangements using the polymerase chain reaction: application to the study of clonal disease cells in acute lymphoblastic leukemiaBlood, 1991
- The immunologic detection of minimal residual disease in acute leukemia [published erratum appears in Blood 1990 Nov 1;76(7):1901]Blood, 1990
- Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.Journal of Clinical Oncology, 1990
- Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequencesBlood, 1989
- Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes.Proceedings of the National Academy of Sciences, 1989
- Detection of Residual Acute Lymphoblastic Leukemia Cells in Cultures of Bone Marrow Obtained during RemissionNew England Journal of Medicine, 1986